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Abstract: Satellite cells are unipotent stem cells involved in muscle regeneration. However, the skeletal 
muscle microenvironment exerts a dominant influence over stem cell function. The cell intrinsic com-
plexity of the skeletal muscle niche located within the connective tissue between fibers includes motor 
neurons, tendons, blood vessels, immune response mediators and interstitial cells. All these cell types 
modulate the trafficking of stimuli responsible of muscle fiber regeneration. In addition, several stem cell types have been 
discovered in skeletal muscle tissue, mainly located in the interstitium. The majority of these stem cells appears to directly 
contribute to myogenic differentiation, although some of them are mainly implicated in paracrine effects. This review fo-
cuses on adult stem cells, which have been used for therapeutic purposes, mainly in animal models of chronic muscle de-
generation. Emerging literature identifies other myogenic progenitors generated from pluripotent stem cells as potential 
candidates for the treatment of skeletal muscle degeneration. However, adult stem cells still represent the gold standard for 
future comparative studies. 
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MUSCLE MICROENVIRONMENT AND INFLAM-
MATION: AN INTRODUCTION  
Skeletal muscle is a complex tissue formed by 
multinucleated syncytial myofibers surrounded by a vast 
heterogeneity of environment-dependent cell types. Motor 
neurons, blood vessels, tendons and bones co-
exist/colocalise with the interstitial cells, located within the 
connective tissue among fibers, to modulate the trafficking 
of stimuli between fibers and connective tissue. Moreover, 
growth factors, as well as secreted molecules and immune 
response mediators control physiological skeletal muscle 
homeostasis. Changes in cellular composition of muscle mi-
croenvironment are crucial for metabolic modifications oc-
curring in acute muscle damage, chronic degeneration and 
regeneration. These processes greatly rely on the activation 
of Satellite Cells (SCs) and their dynamic interaction with 
the surrounding environment. This interplay takes place over 
different time scales. During acute events, such as following 
muscle trauma, it contributes to regeneration after temporary 
atrophic conditions. During chronic events, such as long last-
ing inflammatory processes affecting muscle in genetic dis-
eases (muscular dystrophies or skeletal muscle myopathies) 
and in cancer-induced muscle atrophy and sarcopenia, this 
interplay is still critical to recover muscle function. In acute 
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and chronic skeletal muscle injury, Chemokine Ligand 1 
(CXCL1) or CXCL5, released by mechanically stressed 
muscles, contribute to activation of immune responses. The 
first wave of inflammatory cells arriving at the site of injury 
within two hours after damage is composed of neutrophils 
[1]. Neutrophils enter the site of injury where they release 
reactive oxygen species also cytokines which then cause 
secondary tissue damage and recruit monocytes from the 
blood respectively [2]. Interestingly, when integrin beta-2 
(CD18) is not expressed, neutrophil-recruitment is impaired 
[2] whereas resident macrophages responsible for the innate 
immune response to injury are still present [3]. Circulating 
monocytes, originating from the spleen reach the site of in-
jury in a second wave of inflammatory cells and conse-
quently differentiate into macrophages [4]. 
In muscular dystrophies (MDs), a heterogeneous group 
of inherited diseases characterized by the primary wasting of 
skeletal muscle, the functions of proteins that form a link 
between the cytoskeleton and the basal lamina are affected 
by mutations. Duchenne muscular dystrophy (DMD) is the 
most severe MD due to mutations in the gene encoding dys-
trophin (DMD). Affected patients usually die prematurely 
due to respiratory or cardiac failures [5]. The mdx (muscular 
dystrophy x-linked) mouse, carrying a nonsense point muta-
tion in dystrophin exon 23 is the most used animal model for 
DMD.  
Together with the increased fibrosis, a common hallmark 
of dystrophic muscles, distinct populations of macrophages 
have also been described in the muscle of mdx and affected 
individuals. Macrophages are a heterogeneous population 
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and they can be functionally polarized into M1 (proinflam-
matory macrophages, classically activated) and M2 (alterna-
tively activated) [6]. Macrophages exposed to Interferon-γ or 
Tumor Necrosis Factor (TNF)-α are termed M1 macro-
phages, whereas those exposed to Interleukin (IL)-4, IL-13 
and IL-10 are classified as M2 [7]. While M1 macrophages 
decline in numbers between day 2 and day 4 after acute mus-
cle damage, high levels of M2 macrophages characterize 
subsequent tissue repair [7]. During acute muscle injury, the 
presence of M2 macrophages has been reported [8] but a 
clear understanding of their specific function is still missing. 
M2 macrophages most likely represent two heterogeneous 
populations that differ in time and localization [9]. These 
cells, expressing inducible nitric oxide synthase (iNOS), 
produce TNF-α and IL-1β cytokines. When the inflammation 
process progresses to resolution, macrophages start to ex-
press anti-inflammatory markers such as IL-10 or TGFβ, 
supporting the myogenic and angiogenic programs and fa-
voring deposition of Extra Cellular Matrix (ECM) [9]. The 
transition between these two types of macrophages is still 
under investigation. However, phagocytosis of necrotic mus-
cle cells and releasing of high levels of Interferon-γ (IFN-γ) 
and TNF-α are associated with the M1 phenotype [10].  
T lymphocytes that can differentiate in Th1 and Th2 also 
have defined roles in muscle regeneration. While Th1 in-
flammatory stimuli are responsible for neutrophils and 
macrophages recruitment required to clear cell debris, the 
Th2 immune response sustains the polarization of M2 
macrophage and promotes skeletal muscle healing [11]. De-
lay in muscle regeneration with increased infiltration of 
CD8+ T cells is observed in mice deficient for Cdl-b ubiq-
uitin ligase [12].  
Mast cells can also actively modulate skeletal muscle re-
pair, since they have been shown to accumulate in the gas-
trocnemius muscle 8 hours after injury. Interestingly, they 
are present in mdx muscle tissue close to capillaries and have 
been linked to fibrosis [13]. Since their early appearance at 
the site of inflammation, this cell type is known to produce 
pro-inflammatory molecules, i.e. TNF-α, IL-6 and IL-1. De-
spite this function, a possible role in macrophage polariza-
tion remains to be elucidated.  
In four-week-old mdx mice, M2 macrophages contribute 
to decreasing M1 cells and play a pivotal role in SC activa-
tion and induction of skeletal muscle regeneration [14]. 
Thus, improved therapy that relies on the manipulation of 
specific inflammatory cells is needed [15]. Nevertheless, the 
complexity of the mechanisms regulating the different sub-
populations of cells during inflammation and muscle repair, 
together with fibrosis still need further elucidation. In this 
review, we will describe different muscle associated cell 
types (Fig. 1 and Table 1) that, together with SCs, populate 
skeletal muscle and are involved in the process of muscle 
tissue repair. Finally, we offer an overview of the association 
of genetic and cellular interventions to treat muscle regenera-
tion impairment during pathologic conditions.  
SKELETAL MUSCLE MODULATING CELLS  
Satellite Cells (SCs) 
In the adult, almost half of the body weight is represented 
by striated skeletal muscle tissue. This tissue is able to main-
tain shape and functionality thanks to the occasional fusion 
of muscle precursor cells (MPCs) with existing damaged 
fibers. It is worth noting that with exception for the head 
muscle, all trunk and limb muscle cells originate from an 
embryonic somite source [16]. Indeed, some years ago, Pax3 
expressing precursors were reported for both skeletal muscle 
and smooth muscle cells in the embryonic dorsal aorta, sug-
gesting a common origin before myogenic specification [17]. 
In contrast, cranial paraxial mesoderm is the original tissue 
for almost all of the head muscles, branchiomeric and ex-
traocular muscles [18].  
SCs are located in the adult between the basal lamina and 
sarcolemma of muscle fibers [19] as quiescent unipotent 
stem cells. When activated by muscle damage, SCs enter the 
cell cycle as MPCs and contribute to the formation of new 
muscle fibers. SCs are distinguishable by their tightly 
wrapped shape and the disproportion between their cytosol 
with few organelles and a nucleus. The SC nucleus contains 
condensed chromatin, clearly smaller than the fiber myonu-
clei, due to the quiescence and to the transcriptionally poor 
activity of these cells [20]. SCs are highly abundant in oxida-
tive slow muscles, where they are up to six times more nu-
merous than in fast-glycolytic muscles. In slow muscle, they 
constitute between 2 and 7% of adult muscle nuclei and are 
usually located near blood capillaries [21] or in the proximity 
of the neuromuscular junction. The localization in specific 
anatomical structures and exposure to the signaling niche is 
directly implicated in SC self-renewal. Indeed, SCs can un-
dergo both symmetrical and asymmetrical division, mainly 
depending on the location of their daughter cells with respect 
to the myofiber [22]. Enzymatic digestion and/ or physical 
trituration allows SC release from the myofibers, and several 
protocols of expansion under specific proliferative condi-
tions have been documented [23]. To note, the conditions 
used for the in vitro culture, i.e. specific proliferating me-
dium containing growth factors and collagen-coated dishes, 
are responsible of the activation of SCs, as shown by the 
completely distinct gene expression profile of these cells in 
culture compared with the transcriptome of freshly isolated 
SCs [24]. A deeper understanding of the molecular features 
of these cells in vivo could be useful to better monitor and 
influence the quiescent or the activated and proliferating 
state of these cells in culture. Protocols for isolation by fluo-
rescent-activated cell sorting (FACS) have been largely sug-
gested, taking advantage of the extended panorama of mo-
lecular markers expressed by these cells. Among the ex-
pressed surface markers, cell adhesion protein M-cadherin 
[25], Desmin [26], tyrosine receptor kinase c-Met [27], 
chemokine receptor CXCR4 [28], β1-integrin, syndecan-3 
and syndecan-4 (two main transmembrane heparan sulfate 
proteoglycans) [29], caveolae- forming protein caveolin-1 
[30] and calcitonin receptor [31] are now commonly ac-
cepted. CD34 [32] or the cell surface receptor α7-integrin 
[33], are not specifically expressed by SCs in skeletal mus-
cles, and need to be taken in consideration always in combi-
nation with other specific markers. Among the nuclear mark-
ers, Pax7 is the canonical biomarker for quiescent and prolif-
erating SCs [34], as well as envelope proteins lamin A/C and 
emerin, while the Notch ligand Jagged-1 could be used as a 
marker of activated SCs. The expression of Pax7, neuronal 
cell adhesion molecule (NCAM, also named CD56, [35]) 
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Fig. (1). A. Alkaline phosphatase (AP) staining in murine tibialis anterior muscles from healthy control, Sgca-null (6 month old mice) and 
regenerating muscle (1 week after cardiotoxin injection). The vast of majority of interstitial cells are AP positive (black staining). Nuclei were 
stained in blue with Hoechst. B. scheme of degenerated skeletal muscle with the contribution of both resident myogenic precursors and bone 
marrow derived cells. 
 
Table 1. List of adult stem cells contributing to skeletal muscle regeneration. *Those cells (indirect contributors) contribute to 
muscle regeneration via paracrine effects. 
Cell Type Identification Markers Reference 
 Positive Negative  
Satellite cells (SCs) 
Pax7, M-cadherin, Desmin, cMet, CX-
CR4, Syndecan3/4, CD34, Jagged-1 
CD45, Sca-1, cKit [26, 34, 28-30] 
Mesoangioblasts (MABs) 
AP, NG2, cKit, Flk-1, Sca-1, CD140, 
CD146 
CD45, CD34, CD56, CD144, Pax7 [50, 52-54, 59, 119] 
Interstitial cells (PICs) PW-1, CD34, Sca-1 Pax7, Pax3 [62-64] 
Muscle-Derived Stem Cell (MDSCs) Flk-1, Sca-1, Desmin, CD45, M-cadherin, CD34 [65, 66] 
Side population (SPs) Sca-1/ABCG2, Syndecan4, Pax7 
CD45, CD43, cKit, CD11, Gr-1, 
B220, CD4, CD8 
[68, 69] 
Skeletal muscle-derived CD34+/45- (Sk-34) CD34 Pax7, CD45, CD73 [75, 135] 
Fibro-adipogenic progenitors (FAPs) CD34, Sca-1, CD140 CD45, Lin, CD31, α-7 integrin [78-80] 
Telocytes (TCs) ckit, CD34, PDGFRa CD45, Pax7 [81] 
Fibroblasts Tcf4+ (TCs) Tcf/L2 CD45 [84] 
Bone marrow cells CD45, cKit, Sca-1, CD34 Lin [137] 
Mesenchymal stem cells 
CD29, CD44, CD90, CD76, CD166, 
CD106, CD71, CD73, CD105 
CD45, CD34, CD14, CD133 [46, 139] 
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and c-Met has been shown also in human SCs. Nevertheless, 
the heterogeneity of human SCs is high possibly due to the 
retainment of a more quiescent stage [32]. Accordingly, two 
SC populations have been identified by their mitotic rate 
measured by continuous BrdU labeling. One population is 
responsive and enters the cell cycle as the major population, 
while a reserve population, accounting for 20% of the entire 
population, maintains the quiescent state [36]. Other gene 
expression studies from SCs of different origins (limb and 
head muscles from both adult and aged mice) asserted that 
despite a different gene expression profile, SCs transplanted 
in vivo adopt a specific behavior according to microenvi-
ronment features [37]. The heterogeneous nature of the 
population is also supported by the asymmetric distribution 
of Numb in some but not all the SCs. Numb is a cell fate 
determinant and an inhibitor of the Notch signaling, the dis-
tribution of which contributes to the asymmetric division of 
SCs [38]. This is in agreement with the idea that the prefer-
ential and hierarchical retention of parental chromosomes 
from the most quiescent cells can avoid the accumulation of 
mutations in the DNA strands, probably acquired from the 
daughter cell during replication. A second hypothesis de-
fends the nonrandom segregation of chromatids, with their 
respective epigenetic state, as the main reason for different 
gene expression pattern and cell fate. In this second view, 
one cell corresponds to the satellite stem cell state and the 
other to the satellite progenitor state [39]. Nevertheless many 
questions are still pending regarding the variety of markers 
used to isolate SCs and their function regarding the cell be-
havior. Given their strong myogenic commitment, SCs were 
thought as a major candidate for the treatment of muscular 
degeneration. However, pioneering experiments in mouse 
models showed poor survival and migration of transplanted 
SCs [40]. Although encouraging results have been obtained 
in Phase I clinical trials, SC treatments are hampered by the 
inability of those cells to cross the endothelial barriers, limit-
ing their use to their direct intramuscular introduction. 
Bone Marrow Cells 
Bone marrow mesenchymal stem cells (BM-MSCs) pos-
sess self-renewal ability and multilineage differentiation not 
only to mesoderm lineages, like chondrocytes, osteocytes 
and adipocytes, but also to ectodermic cells and endodermic 
cells [41, 42]. The peculiar characteristic and clinical rele-
vance of MSCs is their ability to release trophic chemokines 
and growth factors that alter the local environment, facilitat-
ing replacement by local progenitors, promoting differentia-
tion and angiogenesis, and exerting anti-apoptotic and im-
munomodulatory properties [43]. In the last 10 years, several 
studies have demonstrated how MSCs can promote myo-
genic regeneration. The first evidence was reported in 1998, 
showing that, the transplantation of genetically-modified 
bone marrow cells into immunodeficient mice, facilitated the 
migration of BM-MSCs into an area of injured muscle pro-
moting regeneration and myogenic differentiation of the 
damaged fibers [44]. Gussoni et al. in 1999 demonstrated 
that wild-type (wt) total BM-MSCs or side population [BM-
SP] cells achieved regenerating skeletal muscle fibers when 
transplanted into dystrophic mice [45]. In 2005, Dezawa et 
al. [46] showed that MSCs forced to express Notch and in-
jected in mdx muscles resulted in a better recovery of dys-
trophin expression. Further studies will be necessary to elu-
cidate the interactions between MSCs and the inflammatory 
milieu, the fate of the implanted cells and beneficial effects 
into damage tissue.  
Pericytes 
Although discovered more than twenty years ago as cells 
surrounding capillaries and able to promote  both angiogene-
sis and tissue repair, pericytes have recently received more 
attention. Indeed, pericytes were initially discovered for their 
ability to counteract and regulate blood flow [47]. In the last 
15 years, these cells have been isolated from a large variety 
of tissues as cells expressing neural-glial-2 chondroitin sul-
phate proteoglycan (NG2; [48]) and Platelet Derived Growth 
Factor-β (PDGF-β) receptor, critical for pericyte survival 
and development [49]. Regarding the expression of α-
Smooth Muscle Actin (SMA), there remain some concerns 
since pericytes in culture express SMA however, only a 
small percentage of pericytes in vivo are SMA positive [48]. 
In human, pericytes have been described as being positive 
for annexin V, alkaline phosphatase, desmin, α−SMA, 
vimentin and to have high levels of PDGF receptor-β, while, 
interestingly, they do not express other markers such as M-
cadherin, N-CAM, cytokeratins and neurofilaments nor en-
dothelial markers (such as CD31, CD34) or hematopoietic 
markers (CD45; [50]). Recently, a new marker profile - 
CD133+, CD34+ and CD56+ and CD45-, has been identified 
for the simultaneous isolation of pericytes, mesenchymal 
stem/stromal cells and blood derived stem cell subpopula-
tions from human samples [51]. 
Mesoangioblats (MABs) 
MABs can be found in the interstitial space between the 
muscle fibers in normal healthy tissue and their presence is 
altered in muscle pathologic conditions. Originally MABs 
have been isolated from dorsal aorta in the mouse embryo at 
day 9.5 of development, and more recently from adult mus-
cle tissue of mice, dogs and humans [52-54]. Embryonic 
MABs express CD34/ c-Kit/ Flk-1 but are negative for 
NKX2.5/ Myf5/ Oct4 [55]. They differentiate to multiple 
mesodermal lineages in vitro and in vivo [56]. In the adult 
mouse and in dogs, MABs are usually extracted from skele-
tal muscle explants as cells positive for Alkaline Phosphatase 
(AP), Stem cell antigen-1 (Sca-1), NG2 proteoglycan, 
CD140a and CD140b [5, 50, 53, 54]. Adult MABs are mul-
tipotent and can differentiate toward myogenic, osteogenic, 
chondrogenic and adipogenic lineages [57]. Finally, human 
MABs also display CD146/ CD140b1/ NG2 but do not pre-
sent any marker of hematopoietic or SCs (CD45-/ CD34-/ 
CD56-/ CD144-/ Pax7-; [50]). To note, a human correspon-
dent to the murine Sca-1 marker is still missing although 
members of human Ly6 proteins have been proposed to have 
homologous functions [58]. Intriguingly, some markers ex-
pressed from human MABs are also characteristic of mesen-
chymal stem cells (CD10/ CD13/ CD44/ CD73/ CD90) and 
supporting the idea of a common origin for mesenchymal 
and pericyte stem cells [59]. Interestingly, a comparison 
among human MSCs, MABs and multipotent adult progeni-
tor cells has confirmed a huge difference between the tran-
scriptomes of these cell populations reflecting their specific 
functional properties and were just partially recovered by 
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culture conditions [60]. Several proinflammatory genes, cy-
tokines and cytokine receptors are also expressed by MABs. 
Indeed, in a recent paper, the exposure to proinflammatory 
cytokines was shown to play an important role in MAB-
induction of immunomodulatory cytokines able to inhibit T-
cell proliferation in vitro [61]. This aspect is not negligible, 
opening the possibility for MABs to undergo new clinical 
applications to modulate immune responses. 
Pw1 Expressing Interstitial Cells (PICs) 
PICs are also located in the interstitium among muscle 
fibers and they are characterized by the expression of PW1 
transcription factor [62]. Analogously to previous cell types 
considered in this review, PICs are Pax7-/ Sca-1+ and CD34+ 
and have been discovered embryonically as cells not related 
to SCs, since they do not have Pax3 myogenic progenitor 
cells, but are probably even able to originate them [63]. 
Transgenic mice carrying the N-terminal portion of PW1 
under the control of a myogenin promoter regulatory se-
quence present normal muscle development in embryonic 
and fetal stages, but, postnatally, these mice show impair-
ment in muscle development reflecting some features ob-
served in Pax7-/- mice [64]. As multipotent myogenic pro-
genitors, PICs are able to differentiate to skeletal and smooth 
muscle, but further studies are needed to better understand 
their origin and their similarity to MABs. 
Muscle Derived Stem Cell (MDSC) 
MDSCs were isolated from the adult muscle tissue based 
on the expression of Flk1, Sca-1 and Desmin and on the ab-
sence of CD45, M-cadherin and CD34 [65]. These cells 
seem to have a different origin from the known SCs since 
they can be successfully isolated from Pax7-/- mice [66] and, 
as other cells populating the interstitial space among the 
myofibers, have been demonstrated to differentiate into my-
ogenic, adipogenic, osteogenic, chondrogenic and even he-
matopoietic lineages [67]. Moreover a low expression of 
Major Histocompatibility Complex (MHC)-1 and conse-
quently the inability to trigger infiltration of activated lym-
phocytes could be promising features for a more successful 
transplantation of these cells [65]. Once again it seems that 
those cells are strongly connected to MABs and conse-
quently to PICs. 
Side Population (SP) 
The term ‘side population’ (SP) is usually referred to a 
small subpopulation of stem cells present in adult muscle 
tissue and bone marrow, isolated for their ability to exclude 
DNA-binding dye (Hoechst 33342). SP cell limiting dilution 
experiments have demonstrated that SPs are able to reconsti-
tute the entire bone marrow of mice lethally irradiated so that 
SPs are able to take different fates in permissive conditions 
[45]. Other groups have identified these cells as positive for 
surface markers like Sca-1/ABCG2 transporter, Syndecan-4 
and Pax7 [68] but negative for hematopoietic stem cell 
markers, including CD43, CD45, c-kit, or immune cell 
markers, such as CD11, Gr-1, B220, CD4 and CD8 [69]. 
Although SPs have somite origins [70], they appear to be 
different from SCs, since still present in Pax7-/- mice [34]. In 
the recent literature, improvements of the expansion of these 
cells have been generated and tested, letting free floating SP 
cells grow in suspension on a myoblast monolayer anchored 
on the surface of microcarriers [71]. Moreover, miR128a 
was found at high levels in SP cells and it was able to main-
tain the quiescent state in SP cells [72].  
SK-34 Cells  
The interstitial space among the fibers has been reported 
as populated by two different cell fractions, such as CD34+/ 
CD45- cells, also called Sk-34, and from CD34-/ CD45- (Sk- 
DN; [73]). Sk-34 is a non-adherent myogenic cell type, not 
able to express Pax7, at least at the isolation, and is charac-
terized by proliferation after muscle damage [74]. Moreover 
these cells, once injected beneath the renal capsule, present 
intrinsic plasticity for differentiation into muscle, pericytes, 
smooth muscle and peripheral nerve cells [75]. In addition, 
these cells are able to secrete nerve and vascular growth fac-
tors [76] making Sk-34 cells suitable as supportive paracrine 
mediators for nerve autografts. This interplay among the 
other interstitial stem cell types needs further investigation. 
Fibro/Adipocyte Progenitors (FAPs) 
Fibroblasts are also present in the interstitial space 
among muscle fibers and they contribute to the extra cellular 
matrix deposition. Fibroblasts, can deposit collagen, laminin, 
fibronectin, tenascin, NCAM and Heparan Sulpate Proteo-
glycans (HSPGs). It has been reported that SCs can undergo 
differentiation to adipocytes or fibroblasts in vitro [77]. 
However, recent studies indicate that muscular adipocytes 
and fibrocytes present under pathological conditions may 
arise from FAPs at various stages of differentiation [78, 79]. 
FAPs were isolated from two independent groups as CD34+/ 
Sca-1+/ Lin-/ CD31-/ CD45-/ α7integrin- [78] or as Sca-1+/ 
CD140a+/ α7integrin- [79] and they exert paracrine positive 
effects on muscle fibers. Interestingly, both groups demon-
strated that these cells do not display myogenic capacity. 
Their positive action is stimulated when Histone Deacetylase 
(HDAC) inhibitors are used to promote follistatin secretion 
[80]. Certainly, it would be interesting to investigate the em-
bryonic counterpart of these cells to better clarify their origin 
and their role in muscle embryonic development. Moreover, 
it would be of great importance to understand which 
chemokine/ growth factor/ endocrine compounds they pro-
duce in healthy conditions. Further studies should later be 
performed in order to also isolate the human counterpart for 
FAPs. Once these goals have been achieved, it may be at-
tractive to use these cells for the treatment of pathologic 
conditions.  
Telocytes (TCs)  
TCs, also referred to as interstitial Cajal-like cells 
(ICLCs), are a recently discovered cell type that populates 
the muscle interstitium. These cells are localized next to cap-
illary and nerve endings, in close relationship with myofi-
bers, SCs and other cell types. TCs express the proliferation 
marker c-kit and are able to transduce intercellular signaling 
via exosomes, ectosomes and multivesicular cargoes [81]. 
TCs are PDGFRβ+/ CD34+ cells and electron and light mi-
croscopy analysis identify their small body (9-15 µm) and a 
certain number of telopodes organized into networks with 
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other cells [82]. Their main function would be the mainte-
nance of tissue homeostasis and through VEGF secretion 
they also stimulate vasculogenesis [83].  
Tcf4+ Fibroblasts 
The transcription factor Tcf4 (transcription factor 7-like 
2; Tcf7l2) is strongly expressed in fibroblast like cells local-
ized in the connective tissue. They have been demonstrated 
using genetic manipulation of Tcf4 (GFPCre) mice to regu-
late muscle fiber type development and maturation [84]. In 
addition, low levels of Tcf4 in myogenic progenitor cells 
promote maturation of muscle fibers. Further characteriza-
tion will be useful to understand the origin of these cells and 
their specific role in skeletal muscle regeneration. 
MUSCLE DAMAGE AND REPAIR 
The modulation of muscle mass and multinucleated fiber 
size depends on protein and myonuclear turnover in case of 
muscle damage. However, the relative role of myogenic pro-
genitors in muscle adaptation and hypertrophy is still ques-
tionable and, according to some authors, muscle hypertrophy 
does not require a de-novo fusion of cells [76]. Usually, mi-
nor lesions caused by spontaneous eccentric contractions, 
wear and tear or small injuries are repaired without the acti-
vation of inflammatory responses or cell implication. Never-
theless, the presence of Ca2+ with intracellular vesicles and 
dysferlin-enriched patches are necessary, as demonstrated by 
the dystrophic-like phenotype in dysferlin-null mice [77]. 
Indeed, as evidenced by limb-girdle muscular dystrophy type 
2B [78, 79] and type 1C [80] in patients harbouring genetic 
mutations, this process requires dysferlin and caveolin-3 
respectively. Conversely, extensive physical and functional 
overload of the muscle after tenotomy [81], removal of syn-
ergic muscles or other experimentally induced/pathological 
conditions [82] can cause traumatic lesions inducing muscle 
regeneration. The entire process can be summarized in three 
phases: 1) necrosis of the existing myofibers and inflamma-
tory responses; 2) activation of interstitial cells with prolif-
eration and differentiation of muscle precursors; 3) new 
myofiber formation that completes the regeneration process. 
Necrosis of the existing damaged fibers induces the leakage 
of the sarcoplasma out of the fiber, resulting in an abnormal 
increase in plasma levels of creatine kinase [83] and miR-
133a [84]. The increased permeability of the membrane is 
usually used as an indication of damage, such as after exten-
sive exercise or in case of degenerative diseases. Experimen-
tally, it is easily detectable since the membrane becomes 
permeable to specific dyes (Evans blue and procion orange) 
[85, 86]. Among, all the molecules that are lost in the blood 
stream, desmin could play a role as a chemoattractant fol-
lowing injury [87]. Moreover, the induced Ca2+ imbalance 
activates proteolysis by calpains able to rapidly degrade 
many proteins including big substrates (e.g. titin and nebulin 
of the Z disk) [88]. Myofiber necrosis simultaneously in-
duces activation of the complement cascade and leucocyte 
inflammatory response from 30 minutes to 2 days after 
bupivacaine (local anaesthetic markedly cardiotoxic) injec-
tion. This process is followed by the activation of macro-
phages [89]. In particular, neutrophils are initially recruited, 
and followed by two different macrophage populations that 
are responsible of the switch between pro-inflammatory and 
anti-inflammatory environments. Indeed, pro-inflammatory 
monocytes sustain myoblast proliferation, while later, upon 
phagocytosis of debris, they switch toward an anti-
inflammatory profile, promoting myoblast differentiation 
into myofibers [6]. Early CD68+/ CD163- macrophages, that 
usually reach their peak in abundance around one day post 
injury before subsequently decreasing, are able to clear cell 
debris and to produce pro-inflammatory cytokines such as 
TNF-α and IL-1. Then CD68-/ CD163+ macrophages become 
predominant up to 4 days post injury, thereby lasting till the 
end of the repair process. This group of cells is responsible 
of secreting anti-inflammatory cytokines, including IL-10. 
Moreover, they seem to induce SC differentiation [90]. A 
further step consists in the repair of the extracellular matrix 
(ECM) around the newly forming fibers, and to give extra-
support to the muscle during contraction [91]. In normal 
conditions, ECM accumulation and basal lamina repair are 
usually under the control of extracellular proteases and their 
inhibitors [92]. An excessive and persistent ECM deposition 
(fibrosis) leads to a defect in the regenerative process. Fibro-
blasts are the main cell type responsible for matrix deposi-
tion: indeed similarly to SCs they can proliferate and migrate 
to the injury site immediately after damage [93]. Chronic 
inflammation plays a crucial role in severe myopathies such 
as DMD where endomysial fibrosis is a myopathological 
feature responsible of poor motility and later on fatty re-
placement [94]. Depending on the entity of the damage and 
on the conditions of the tissue, the appearance of small 
centro-nucleated myofibers, often positive for embryonal 
Myosin Heavy Chain and not always completely fused, is a 
common hallmark [95]. Formation of branched myofibers is 
classic feature of neuromuscular diseases accompanied by 
the presence of scar tissue [96]. Finally, when muscle regen-
eration is almost complete, new myofibers can undergo hy-
pertrophy, due to contractile protein synthesis, and the single 
myonuclei migrate to the fiber periphery, generating func-
tionally mature muscle fibers.  
The activation of SCs is characterized by the exit from a 
quiescent state to a proliferative one. CD34 is highly ex-
pressed in quiescent SCs but strongly down-regulated during 
SC activation. This anti-adhesive molecule seems to facili-
tate cell migration and promotes proliferation during the 
early phases of SC activation [97]. Analogously, when SCs 
are activated, they can be directed to the site of injury due to 
a dynamic expression of Ephrin receptors and ligands [98]. 
Intracellularly, SCs shift from the expression of Pax7 to a 
gradual expression of the Muscle Regulatory Factors (MRFs, 
master regulators), namely Myf5, MyoD, Mrf4 and Myo-
genin, which subsequently drive the skeletal myogenesis 
[35]. Myf5 locus is active in almost 90% of quiescent SCs, 
suggesting that almost the total number of these cells is 
committed to the myogenic lineage [33]. Interestingly, the 
ratio among the levels of expression of these transcription 
factors is a determinant of SC fate. Indeed, Pax7 decreases 
MyoD transcription activity and stability, while Pax7 tran-
scription is thereby repressed by Myogenin, once the cells 
are completely differentiated [99]. This is mediated by for 
example High Mobility Group Box-1 - Receptor for Ad-
vanced Glycation End-products (HMGB1-RAGE) axis 
[100]. Whether this ratio is maintained or not, impairment in 
regenerative capacity is observed, such as during cancer-
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induced muscle atrophy [101]. One day after activation, SCs 
express either MyoD or Myf5 while both are coexpressed at 
day 2 [102]. Interestingly, in vitro or in vivo ablation of 
Myf5, MyoD or Mrf4 results in only mild myogenic abnor-
malities, while genetic ablation of all three transcription fac-
tors abolishes myogenesis [103]. MyoD-null mice display a 
reduced muscle mass and an impairment of muscle regenera-
tion [104]. Analogously, when MyoD is missing, low levels 
of Myogenin are expressed, stressing the hierarchical impor-
tance of these transcription factors in achieving specification 
[105]. Conversely, the ectopic expression of MyoD in fibro-
blasts is sufficient to induce differentiation to myotubes un-
derlying the crucial importance of this DNA-binding protein 
for skeletal muscle fate [106]. The transcriptional activity of 
MyoD and of the downstream Myogenin and Mef2s acti-
vates muscle specific genes for structure and functionality, 
including actin, myosin and troponin genes [107]. 
DIRECT CONTRIBUTION OF ADULT STEM CELLS 
TO SKELETAL MUSCLE REGENERATION  
The pivotal and non-redundant role of SCs delineates a 
large consensus in the scientific community of myologists 
regarding the fact that skeletal muscle regeneration does not 
occur without SCs. However, the emergence of interstitial 
stem cells are questioning of the precise role of SCs since 
also interstitial cells direct contribute to adult myogenesis 
and they are crucial in promoting differentiation and resolv-
ing inflammation. Physiological and pathological conditions 
can induce muscle differentiation that normally is addressed 
by SCs during extensive exercise or muscle injury [85, 86]. 
Indeed, the SC pool can increase during four days after a 
single session of exercise and can drastically reduce when 
exercise ceases [87]. Besides, exposure to γ- or X-ray radia-
tion can block overload- or exercise- induced SC activation 
[88]. Interestingly, following exercise, a quantitative increase 
in the number of Myf5-expressing cells of approximately six 
fold was observed up to 96 hours after the training session, 
confirming that muscle SCs are the primary responders to 
exercise-induced stress and consequent muscle re-
pair/adaptation [89]. From the second day after injury, the 
generation of Sphingosine-1-Phosphate (S1P) seems to be 
required, since in its absence, SCs do not proliferate and 
support regeneration [90]. As a bioactive lipid, S1P is able to 
modulate many signaling pathways, and it is involved in 
cell- to -cell interaction, cell survival and proliferation [91]. 
Recently, the sphingosine kinase/S1P axis has been recog-
nized as critical in the migratory mechanism of SCs [92]. 
Moreover, S1P promotion of SCs entry into the cell cycle 
has been demonstrated as dependent upon STAT3 activation. 
In addition, the inhibition of the catabolic enzyme sphingos-
ine phosphate lyase could suggest a therapeutic strategy for 
muscular dystrophies [93]. Nitric Oxide (NO) is important 
for SCs since it activates matrix metalloproteases able to 
induce the release of Hepatocyte Growth Factor (HGF). Fol-
lowing HGF activation of the receptor c-Met, SCs start to 
proliferate [94]. SC proliferation seems to be regulated by 
Notch and Wnt signaling, within a fine chronological pattern 
[95]. In addition, SCs of adult mice with abolished Notch 
signaling undergo spontaneous activation from the quiescent 
state to differentiation, resulting in depletion of the SC pool 
and failure of muscle regeneration [95]. Moreover, the ab-
sence of Hesr1 and Hesr3, Notch signaling downstream tar-
get genes, usually expressed in quiescent SCs, induces re-
duction of SC self-renewal and depletion of the SCs pool, 
leading to the consequent impairment of muscle regeneration 
[96]. Wnt signaling pathway is necessary for muscle differ-
entiation and for myogenic commitment of stem cells, and it 
is also involved in fibrosis during aging [77]. Wnt induces 
the differentiation of proliferating myoblasts if activated at a 
correct time, since premature Wnt activation induces an an-
ticipated but not sufficient differentiation stimulus [97]. 
Thus, in vivo Wnt7a injection into injured muscles contrib-
utes to the myogenic program as reported by an increase in 
muscle mass and cross sectional area [98]. It is possible that 
in regenerating muscles, Wnt/β-catenin pathway increases 
Wnt7a production and activation of SCs, with replenishment 
of SC pool [21]. This could be the reason why recently, ex 
vivo stimulation of freshly isolated SCs with Wnt7a for a few 
hours resulted in amelioration of the migration ability of 
these cells when injected into new mice. Indeed, the trans-
plantation resulted in a massive increase in engrafted cells 
and a hypertrophic effect upon the newly formed myofibers, 
with higher muscle force [99]. Furthermore, Wnt/β-catenin 
downregulation, modulated by Wnt10b, a protein of the 
Wnt-family, induces an increase in adipogenic differentiation 
in the elderly [100]. According to this observation, Wnt10b-
null mice show excessive lipid accumulation during muscle 
regeneration [101]. Further studies are needed in order to 
shed a light on the complexity of Wnt signaling and its abil-
ity to induce adipogenic and myogenic differentiation.  
Myofibers secrete SDF-1, a migration factor that binds 
CXCR4 receptor on SCs, influencing their movement [28]. 
Moreover, after injury, the Notch ligand Delta has been 
found upregulated on myofibers, thus able to activate pro-
liferation of quiescent SCs. Interestingly, in the same study, 
the reduction in Notch signaling could compromise SC 
activation and muscle regeneration [102]. The entire regen-
erative process is also promoted by a series of growth fac-
tors, present in the interstitium or in the serum, that can 
extend or make effective the induction of SCs towards dif-
ferentiation. The overexpression of pro-migratory stimuli 
like MM9 or VEGF in skeletal muscle promotes angio-
genesis and improves the engraftment of transplanted 
myoblasts [103]. HGF mediates different processes, includ-
ing cell proliferation, migration and motility. In skeletal 
muscle, HGF function is mainly characteristic of the early 
phases of regeneration, since muscle injury would increase 
NO levels and activate the MMP responsible for its prote-
olytic cleavage [104]. HGF acts through its receptor c-Met, 
usually expressed by both quiescent and proliferative SCs, 
stimulating the entrance in cell cycle [27] and inhibiting 
cell differentiation through a sustained MAPK/ERK signal-
ing [105]. Mice expressing an engineered protein (Met-
Activating Genetically Improved Chimeric Factor-1 or 
Magic-F1) with two repeated Met-binding domains display 
muscle hypertrophy and SCs are protected from apoptotic 
events [106]. FGFs have been reported to affect skeletal 
muscle regeneration. FGF6-/- mice show impaired regenera-
tion, with reduction of MyoD and Myogenin expression 
cells, and accumulate scar tissue and collagen deposition in 
skeletal muscle tissues [107]. In vitro, FGF-1 inhibition 
induces myogenic differentiation, while exogenous FGFs 
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stimulate proliferation of rat primary myoblasts [108]. In-
terestingly, it has been shown that alpha-Sarcoglycan 
(Sgca) deficiency could cause reduction in FGF-R1 expres-
sion and consequently impairment of SC proliferation in 
response to basic Fibroblast Growth Factor (bFGF) [109]. 
SC activity is also regulated by Insulin like Growth Factor 
(IGF-1) and IGF-2 [110] that induce activation of MRFs 
[111]. Two main signaling pathways are activated down-
stream of IGFs. The phosphatidylinositol 3-kinase (PI3K) 
pathway, that elicits an antiapoptotic effect mainly medi-
ated through AKT/ mTOR [112] and the AKT/ p38-MAPK 
pathway that is involved in myoblasts differentiation [113, 
114]. The Ras/ Raf/ extracellular response kinases (ERK) 
signaling cascade is also crucial for SC proliferation [115]. 
Notably, enhanced myoblast proliferation is obtained after 
stimulation with mechano-growth factor (MGF), which is 
derived by alternative splicing of the IGF-1 gene [116]. 
Interestingly, co-injection of myoblasts and IGF-1 or bFGF 
was able to double the migration distance of the cells, al-
though without increasing SC engraftment [117]. Indeed, 
the poor transendothelial migration abilities of SCs still 
remain one of the major limiting factors that make SCs 
inadequate for systemic delivery. Moreover, SCs easily 
undergo senescence after isolation, expansion and manipu-
lation and result in a reduced engraftment due to immune 
rejection and poor survival [118]. For all of these reasons, 
novel candidate progenitors with myogenic proliferative 
and migratory capabilities are increasingly necessary.  
Pericytes and Skeletal Muscle Regeneration  
To date, several studies have demonstrated the ability of 
pericytes to differentiate to skeletal muscle giving rise to 
functional muscle fibers and smooth muscle layer of blood 
vessels [119-121]. The contribution of pericytes to skeletal 
muscle varies among different muscles and is enhanced 
after acute injury or in the presence of chronic disease. 
However, in chronic conditions pericytes seem to mainly 
contribute to fibrosis as observed in type I diabetic and 
nephropathy, which implies conversion of pericytes into 
myofibroblasts [122]. Interestingly, AP+ cell increment in 
biopsies coming from different dystrophic patients could be 
interpreted as an attempt to regenerate muscle tissue [123]. 
Lately, two different pericyte populations (type-1 and -2) 
have been distinguished and their commitment and com-
plete differentiation to skeletal muscle have been correlated 
to the expression of Nestin [121]. Indeed, type 1 pericytes, 
negative for the Nestin marker, seem to contribute to the 
deposition of collagen in old mice [124]. Nevertheless, fur-
ther studies are needed to determine if the absence of the 
specific type-2 subpopulation can really determine impair-
ment in skeletal muscle regeneration. Also, to identify 
whether other markers are selectively expressed on the two 
different populations that can be employed to selectively 
isolate type-2 pericytes and further investigate a possible 
applicability of these cells. 
MABs and Skeletal Muscle Regeneration  
Intrinsic properties of migration and survival while in the 
circulation and in their high efficiency of transplantation 
inducing high regeneration abilities have been observed in 
MABs. Indeed, injection of Sgca-null MABs, after correc-
tion for the missing protein into Sgca-null mice (mouse 
model used for LGMD) gave rise to Sgca+ myofibers [53]. 
Moreover, Human MABs injected in the femoral-artery of 
mice with combined immune deficient-X- linked muscular 
dystrophy (scid-mdx) gave rise to dystrophin+ myofibers 
[50]. In addition, several factors can ameliorate the migration 
from blood vessels towards the injured tissue and the en-
graftment of MABs, like HMGB1, SDF-1, CXCR4 and α4-
integrin [125]. Similarly nitric oxide pretreatment of MABs 
can improve their therapeutic potential [126]. Recently, 
technological improvements for gene correction as Piggy-
Bac-mediated approaches make MABs more suitable for 
further studies in muscle regeneration [127]. Moreover, gain 
and loss of function experiments have revealed that Delta-
like ligand 1 (Dll1)-activated Notch1 and Mef2C supports 
MAB commitment in vitro and induces a strong amelioration 
of their engraftment in vivo [128]. Finally, preliminary data 
from Phase I/II clinical trials using HLA-identical allogeneic 
MABs (EudraCT number 2011-000176-33) indicate safety 
and presence of donor derived DNA and dystrophin in 
treated patients (Table 2). Further studies still need to be 
done, in order to understand if other pathways, such as BMP-
and Wnt signaling can be involved in myogenic potential and 
cell engraftment, in order to corroborate MAB regenerative 
potential. 
PIC Cells 
PIC myogenic potential has been proved in vitro [63]. 
Moreover, when these cells are injected in injured muscles, 
surface marker analysis has revealed that these cells are able 
to repopulate not only the interstitial fraction of PIC cells, 
but as well, the fraction of Pax7+ cells, letting space for 
speculation about the myogenic potential of these cells in the 
adult [63, 80]. Some other issues on the possible origin of 
PICs have been proposed and are of significant interest, 
since some of the markers of PICs and FAPs are in common 
(CD34+/ Sca1+/ CD45-) and these two cell types share the 
same localization (Fig. 1). Quite recently, PICs were demon-
strated to differentiate to adipose cells [129], opening the 
discussion on the possible overlap between interstitial popu-
lations such as FAPs and PICs. How the Pw1 transcription 
factor is silenced in the adipocyte cell conversion is still un-
der investigation. 
MDSCs and Skeletal Muscle Regeneration 
As the MABs, intra-arterial transplantation of MDSCs 
contributes to regenerate myofibers [130] and differently 
from MABs they give rise to endothelial and neural cells 
[65]. Moreover, MDSCs have also the capability to repopu-
late the hematopoietic pool in lethally irradiated mice, induc-
ing muscle repair [131]. The relationships between MDSCs, 
MABs and other myogenic cells are still unknown and fur-
ther translational investigation is necessary to better under-
stand the therapeutic potential of MDSC. 
SPs and Skeletal Muscle Regeneration 
SPs have been induced to undergo myogenic commit-
ment by co-culturing them together with myoblasts or forc-
ing Pax7 or MyoD expression [132]. A subpopulation of SPs 
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Table 2. A partial list of interventional trials for muscular dystrophies based on adult stem cell treatments.  
Study 
(Code) 
Purpose 
Phase 
[Patient Number] 
Intervention 
[Dose] 
Ages 
Genders 
Status Locations 
Safety and efficacy of bone mar-
row derived autologous cells 
(NCT01834066) 
Safety and efficacy of 
bone marrow derived 
autologous cells 
Phase1/2 
(25) 
Intravenous 
delivery 
(100 MIO) 
6 -25 y 
male/female Recruiting India 
Efficacy of umbilical cord MSCs 
(NCT02285673) 
Efficacy of umbilical cord 
MSCs 
Phase1/2 
(10) 
NA 
7-20 y 
male 
Recruiting Turkey 
Allogeneic human umbilical cord 
MSCs 
(NCT02235844) 
Muscle regeneration and 
anti-inflammatory proper-
ties of umbilical cord 
MSCs 
Phase1 
(1) 
NA 
28-31 y 
male 
Enrolling by 
invitation 
USA 
Stem Cell Therapy in DMD 
(NCT02241434) 
Autologous bone marrow 
mononuclear cell therapy 
Phase1 
(500) 
NA 
3-25 y 
male/female 
Recruiting India 
Safety and efficacy of BMMNC 
for DMD patients 
(NCT01834040) 
Single arm, single centre 
trial to check the safety 
and efficacy of BMMNC 
transplantation 
Phase1/2 
(30) 
Intravenous 
delivery 
(100 MIO) 
4-20 y 
male/female 
Recruiting India 
Intra-arterial delivery of HLA-
identical allogeneic MABs 
(EudraCT 2011-000176-33) 
Safety and improvement 
of muscle strength of local 
and systemic adverse 
events 
Phase1 
(6) 
Intra-arterial 
delivery 
(escalating dose) 
< 18 y 
male 
Active, not 
recruiting 
Italy 
Cell therapy in limb girdle mus-
cular dystrophy (LGMD) 
(NCT02245711) 
Effects of stem cell ther-
apy on LGMD patients 
Phase1 
(200) 
Intrathecal  
delivery 
(NA) 
15-60 y 
male/female 
Recruiting India 
Intramuscular transplantation of 
MSCs in patients with faci-
oscapulohumeral dystrophy 
(FSHD) 
(NCT02208713) 
Evaluation of safety and 
feasibility of muscle and 
adipose derived MSCs in 
FSHD 
Phase1 
(15) 
Intramuscular 
delivery 
(NA) 
18-50 y, 
male/female, 
no volunteers 
Recruiting Iran 
 
characterized by CD45-/ Sca-1+/ ABCG2+/ Pax7+/ Syndecan-
4+ marker profile has been found to differentiate into myofi-
bers and undergo self- renewal in the quiescent compartment 
after in vivo injections [45]. Importantly, these cells can en-
graft and restore the levels of dystrophin when intravenously 
injected into mdx-mice [45, 133].  
SK-34 and Skeletal Muscle Regeneration 
Sk-34 cells have also been successfully transplanted in 
vivo and have demonstrated great differentiation potential 
not only towards the skeletal muscle tissue, but as well to-
wards the endothelial and the Schwann cells [134]. Appar-
ently these cells are even able to undergo differentiation to-
wards cardiomyocytes and, when injected into the infarcted 
heart, improve left ventricle functionality [135]. The great 
utility of these cells indeed is their ability to give rise to dif-
ferent lineages. Many questions remain to be solved in order 
to understand the best way to apply them in preclinical and 
clinical trials however. 
Circulating Bone Marrow Cells and Skeletal Muscle Re-
generation 
Intramuscular and intravenous injections of bone marrow 
derived cells into injured muscles have demonstrated the 
possibility for these cells to regenerate skeletal muscle [44], 
even if the ability to reconstitute the SC niche was consid-
ered low. Nevertheless, systemic injection into irradiated 
mice could reconstitute the Myf5+, c-Met+ and α7integrin+ 
SC pool [136]. Adult bone marrow-residing hematopoietic 
stem cells, isolated for the positivity for c-Kit/ Sca-1/ CD45 
in different association, are all able to fuse into newly 
formed myofibers [137]. Interestingly, muscle stress and 
injury could be two major stimuli to improve engraftment of 
bone marrow cells into regenerating muscles [138], provid-
ing further proof that the microenvironment can guide cell 
specification. Indeed, bone marrow cells have been demon-
strated to depend on SDF-1/ CXCR4 signaling, chemokine 
receptor 2 (CCR2), and on the Hepatocyte Growth Factor 
(HGF)/c-Met axis [28]. 
Mesenchymal Stem Cells (MSCs) have been character-
ized as CD29+/ CD44+/ CD71+/ CD73+/ CD90+/ CD105+/ 
CD106+/ CD166+, CD34-/ CD45- and have been cultivated in 
vitro as adherent growing cells able to differentiate under 
specific conditions to various lineages, including osteogenic, 
chondrogenic, adipogenic [139]. Further progress in devel-
oping strategies to enhance MSC commitment toward skele-
tal muscle will no doubt arise through research into new and 
important signaling pathways. Indeed, co-culture of MSC 
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and C2C12 myoblasts have reported to induce Notch signal-
ing pathway and VEGFR phosphorylation and expression 
[140]. Moreover, the same research group has recently dem-
onstrated that S1P, a natural bioactive lipid that binds to a 
family of five G protein-coupled receptors, is secreted by 
MSCs and is one of the stimulatory effectors of these cells 
on C2C12 myoblast and SC proliferation [141]. Neverthe-
less, despite the exciting results in preliminary pre-clinical 
studies with BM-MSCs, there are still several unanswered 
questions and we are currently in the dark about their clinical 
relevance. 
HSCs and Skeletal Muscle Regeneration 
From human adult peripheral blood, a fraction of mono-
nucleated cells (CD133+) shows myogenic potential when 
co-cultured together with myoblasts or in presence of Wnt7a 
secreting fibroblasts [142]. Indeed these cells, which are able 
to repopulate the bone marrow niche and to differentiate into 
endothelial cells, have been injected intramuscularly in 
scid/mdx mice, giving rise to dystrophin positive myofibers 
[142]. Surprisingly, human M-cadherin and Myf5 genes 
were detected in the undifferentiated compartment of these 
muscles, testifying the ability for these cells not only to en-
graft but as well to replenish the SC niche [142]. After these 
experiments, CD133+/ CD34+ cells have been identified in 
skeletal muscle biopsies of different musculopathies, such as 
dermatomyositis, polymyositis and inclusion body myositis 
[143]. Human muscle-derived stem cells expressing hema-
topoietic markers like CD133 have been injected intramuscu-
larly in cryo-injured Rag2-/- gamma-/- C5-/- mice (an experi-
mental model of muscle degeneration), increasing regenera-
tion [144]. These cells have also been employed to treat scid-
mdx mice [145], and in an autologous setting in a phase I 
clinical trial (Table 2) resulting in an increased number of 
capillaries associated with muscle fibers and a slow to fast 
fiber switch [146]. Recently, antisense oligonucleotide-based 
experiments have demonstrated a partial rescue of dysferlin 
levels in CD133+ stem cells isolated from patients with Mi-
yoshi myopathy and subjected to myogenic induction. In 
addition, dysferlin-transduced CD133+ stem cells were able 
to affect positively the dystrophic phenotype of transplanted 
scid/blAJ dysferlin-null mice [147].  
INDIRECT CONTRIBUTION TO SKELETAL MUS-
CLE REGENERATION  
FAPs and Skeletal Muscle Regeneration 
As already reported, FAPs are not able to give rise to 
skeletal muscle cells. However, they are crucial for the 
paracrine modification of the skeletal muscle niche to modu-
late adult myogenesis. The activation of IL-4/IL-13 signaling 
induces FAP proliferation and supports myogenesis, inhibit-
ing the adipogenic potential of these cells [148] [149]. Re-
cently, it has been demonstrated that glucocorticoids can 
further worsen muscle degeneration, since dexamethasone 
administration blocks IL-4 secretion and stimulates adipo-
genic commitment of FAPs [150]. Moreover, it has been 
hypothesized that Nitrix-Oxide (NO) not only improves re-
generation but reduce the number of PDGFRα+ cells, the 
synthesis of connective tissue and deposition of fat into the 
skeletal muscle tissue in dystrophic muscle. Consistently NO 
inhibits FAP adipogenic differentiation through increased 
expression of miR-27b [151]. Finally, epigenetic-modifying 
drugs have been revealed to be interesting tools to influence 
FAP differentiation fate decisions. Indeed, the BAF60c–
myomiR axis has been identified as a key mediator of 
HDAC inhibitor-induced changes in FAP plasticity [152]. 
The mechanisms that induce the changes in chromatin struc-
ture and that permit the activation of the myomiR/BAF60c 
network still need to be clarified. 
TCs and Skeletal Muscle Regeneration 
Another supporting role in muscle regeneration is appar-
ently played by the interstitial telocytes, expressing 
PDGFRα and c-kit markers. They release VEGF and are 
able to form networks. Moreover, all of these characteristics 
have been confirmed in human TCs, suggesting their clini-
cally relevant role in skeletal muscle regeneration and repair, 
at least after trauma [81]. Further studies will be needed in 
order to clarify the function of these cells and their interac-
tion with the local milieu and with other cells. 
Tcf4 Positive Fibroblasts and Skeletal Muscle Regenera-
tion 
Tcf4 positive fibroblasts have an important paracrine ef-
fect during adult myogenesis, since ablation of SCs not only 
impairs muscle regeneration but also interferes with Tcf4 
fibroblast function and leads to an increase in connective 
tissue. This is a mutual phenomenon since the lack of Tcf4+ 
fibroblasts results in a premature SC differentiation leading 
to abnormally small regenerated myofibers [85]. Further 
studies need to be conduced in order to identify the signaling 
pathways that can orchestrate such a strict communication 
between Tcf4 positive fibroblasts and SCs. 
GENE EXPRESSION MODIFICATION FOR CELL-
BASED THERAPIES 
MPCs from healthy donors have been extensively pro-
posed as the main sources for cell-based therapies in MDs. 
Unfortunately, poor survival and migration of MPCs and 
also possibly an immune response to donor represents sig-
nificant barriers? to therapeutic development [153]. Ex vivo 
gene therapy allowed delivery of therapeutic genes into 
MPCs before transplantation and has been proposed as a 
treatment for DMD. Since full-length dystrophin transferring 
showed several methodological issues because of its size (14 
kb), several alternative strategies have been explored. A 
nonviral approach combining nucleofection and the phiC31 
integrase provided a safe site-specific integration of the 
transgene [154]. However, adeno-associated virus (AAV) 
and lentiviral vectors were so far the main proposed tools for 
micro- or mini-dystrophin transduction in MPCs. Neverthe-
less, the lack of genomic integration of AAV and the scarce 
lentiviral transduction in myofiber cultures directly limit 
their therapeutic potential. In addition, although lentiviral 
vectors guarantee genome integration and stable expression 
[155], they have a maximum of 10 kb cloning capacity, pre-
cluding their use for delivering the full-length 14-kb dystro-
phin cDNA. Thus an exon-skipping strategy was introduced 
in ex vivo gene therapy as potential treatment of DMD. 
Exon-skipping acts by RNAs (i.e. U7) or DNAs able to inter-
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fere with the normal splicing and restore the open-reading 
frame of mutated dystrophin. In this way exon-skipping 
technology induces the splicing machinery to skip the mutant 
exons in missense, nonsense, and eventually translationally 
silent mutations. In 2007 Quenneville and colleagues dem-
onstrated the applicability of lentiviral-based ex vivo gene 
therapy using modified DMD-derived MPCs with micro-
dystrophin expression or U7 based exon-skipping strategies 
in both the mdx mouse and in non-human primates [156]. 
The AAV-mediated exon-skipping strategy has also been 
adopted in genetic correction of CD133+ myogenic progeni-
tors isolated from both skeletal muscle tissue and blood of 
DMD patients. Intra-arterial transplantation of these cells in 
scid/mdx mice showed an appreciable rescue in dystrophin 
expression, consequently restoring muscle structure and 
functionality [145]. Recently it has been shown that culture 
of human muscle fiber fragments can be used as a source of 
SCs which are genetically manipulable for the expression of 
the myogenesis regulator Pax7 through Sleeping Beauty 
transposon–mediated nonviral gene transfer [157]. Since 
entire fragments can be implanted in vivo, this method high-
lights the possibility of combining gene expression modifica-
tion with a high efficiency of human satellite cell transplan-
tation in an animal model for muscular dystrophies [157].  
TALEN (transcription activator-like effector nucleases) 
and CRISPR (clustered regularly interspaced short palin-
dromic repeats) genome-editing approaches provide an 
efficient strategy for correcting point mutations. TALENs 
are endonucleases with a TAL effector DNA binding do-
main and a DNA cleavage domain able to induce a double 
strand break (DSB) in the DNA followed by homologous 
recombination. CRISPR is an RNA-guided gene-editing 
system able to introduce a double strand break by deliver-
ing the Cas9 protein and appropriate gene specific guide 
RNAs. CRISPR/Cas9-mediated genome editing was re-
cently used to correct the mutation in dystrophin exon 23 in 
the germ line of mdx mice [158]. Using three correction 
methods (exon skipping, frameshifting, and exon knockin) 
in DMD-patient-derived iPSCs TALEN and CRISPR-Cas9 
technologies were employed to restore the expression of 
dystrophin [159]. In this study, Li et al showed that exon 
knock-in was the most effective approach and TALEN and 
CRISPR-Cas9 corrected iPSCs were able to differentiate 
into skeletal muscle cells and express the full-length dys-
trophin protein. These are very promising gene editing 
technologies that will be further developed and so far no 
clinical trials are yet planned. 
CELL-BASED THERAPIES IN MUSCLE REGEN-
ERATION: ADVANCES AND LIMITATIONS 
According to the type and the stage of the muscular dis-
order, the failure in muscular regenerative capability is an 
important determinant of muscle wasting [160]. Inflamma-
tory cells, from different origins, can strongly participate in 
the events underlying muscular disruption occurring in 
chronic degenerative diseases, such as in dystrophinopathies, 
or in a mild way as observed in cancer-related muscle wast-
ing. These cells, together with the prominent effects medi-
ated by both local and circulating pro-inflammatory media-
tors, can contribute to the altered muscle regeneration capa-
bility observed in the majority of muscular diseases. Overall, 
chronic local inflammation and hampered regeneration po-
tential lead to the increased susceptibility to damage in mus-
cle fibers that become atrophic and replenished by fibrotic 
tissue. Many efforts have been made aiming to treat severe 
muscular illness using a cell-based therapeutic approach, 
especially in MDs [160]. Skeletal muscle-resident progeni-
tors cells are the most adopted sources experimented so far 
including SCs, pericytes, FAPs, PICs, MDSCs and SP, while 
among interstitial stem cells, MABs have been investigated 
as potential candidates for therapeutic approaches, in the 
treatment of sarcoglycanopathies and dystrophinopathies. 
Among the most common muscular degenerative diseases, 
MDs are indeed characterized by both impaired myogenic 
stem cell function and extreme deposition of extracellular 
matrix [161]. The early-aged onset, the premature death, the 
decreased quality of life of the patient and the high socio-
economic burden [162] together with limitations related to 
human myoblast transfer therapy, have encouraged the in-
vestigation of stem cell sources other than SCs. Thus, the 
research in cell-based therapies for treatment of muscle de-
generation has been oriented toward MABs and pericytes. 
These alternative sources of cells are more abundant, more 
accessible and show a better motility after transplantation 
compared to SCs [157]. MABs show a strong ability to cross 
the vessel wall and intra-arterial delivery of mice lacking α-
SG, a limb-girdle model of muscular dystrophy, demon-
strated promising results in amelioration of the dystrophic 
phenotype [53]. Furthermore, recent advances in skeletal 
muscle tissue engineering showed that the use of specific 
scaffold tissues supporting progenitor/stem, such as polyeth-
ylene glycol (PEG)–fibrinogen [163], ameliorates both sur-
vival and engraftment of transplanted MPCs [164]. Cell-
based therapies for muscle disorders still represent a road 
under construction and likely all of these emerging technolo-
gies will be combined together to test novel therapeutic 
strategies [160].  
MIRNAS AND EXOSOME  
In the last decade, many high level publications showed 
the critical roles of micro-RNAs (miRNAs) in regulating 
biological phenomena, including stem cell fate and skeletal 
muscle regeneration. MiRNAs are non-coding RNAs able to 
modify gene expression through altering mRNA stability or 
inhibition of translation. miRNAs sit in the genome either as 
individual transcriptional units or are co-transcribed as in-
tronic sequences of other genes [165, 166]. The biogenesis 
of miRNAs consists in the generation of pri-miRs by RNA 
polymerase II that are processed by the microprocessor 
complex into pre-miRs [167]. Exportin is responsible for 
pre-miRs transportation to the cytosol and Dicer cleaves 
them into ~22nt-long double-stranded molecules. The guide 
strand is on the RNA-induced silencing complex (RISC) 
that is able to carry out gene silencing by recognizing 3’ 
untranslated region (3’-UTR) of target mRNAs [168]. Sev-
eral miRNAs have been shown to be involved in skeletal 
muscle homeostasis controlling embryonic and adult myo-
genesis. Recently, they have also been proposed as diagnos-
tic markers in DMD serum derived patients (NCT02109692; 
Table 2). Mir-206, MiR-1 and miR-133 represent the myo-
miRNA family, since they are highly expressed in skeletal 
muscle tissue and regulate its regeneration [169]. Evidence 
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is also accumulating for broadly expressed miRNAs that 
display a critical effect on muscle remodeling. Mir-24 [170] 
and mir-29 [171, 172], for instance, are ubiquitously ex-
pressed but they have an impact on myogenesis by repress-
ing TGFβ signaling and the Polycomb silencing complex 
respectively. In addition, mir-29 can target the tyrosine 
kinase Akt3, associating it with growth factor signaling 
[173]. A remarkable example of miRNA-mediated cell fate 
shift consists of miR-669a/q, able to control MyoD expres-
sion in murine cardiac progenitor cells. Scgb-null mice 
show impairment in miR-669a/q expression resulting in 
aberrant differentiation of cardiac MABs that can be rescued 
by AAV miR-669a-based therapy [174, 175]. Although fur-
ther studies are necessary to better interpret the role of 
miRNAs in adult stem cell biology and skeletal muscle re-
generation, miRNAs are definitely key players in muscle 
regenerative medicine. Another open question is regarding 
how miRNAs can mediate cell-cell interactions. Emerging 
literature is focusing on the role of exosomes, extracellular 
vesicles containing proteins and RNAs including miRNAs 
[176]. Exosomes released during muscle cell differentiation 
contain myomiRNAs and paracrine action of exosomes se-
creted by stem cells has been also reported, suggesting a key 
role for exosomal miRNAs in intracellular communication. 
Mesenchymal stem cells release exosomes that activate an-
giogenesis and myogenesis pathways facilitating skeletal 
muscle repair. MyomiRNAs likely carried by exosomes are 
detected in body fluids of animal models of muscle degen-
eration and their presence was further confirmed in patients 
affected by muscular dystrophies [177]. Exosome-miRNAs 
are now considered putative biomarkers in muscle degen-
eration/regeneration and are providing a new impetus for the 
exploration of novel therapeutic approaches for muscular 
degeneration [177]. 
CHALLENGES AND FUTURE PERSPECTIVES 
Promising results have been obtained from the transplan-
tation of engineered mouse embryonic stem cells (ES) condi-
tional expression of Pax3 and Pax7. ES Pax3/Pax7 showed 
high ability to engraft in the satellite cell niche through sys-
temic injections, prolonged self-renewal predisposition and 
an excellent response to injury. Although this approach still 
did not reach the clinic, these findings support the therapeu-
tic relevance of ES-derived myogenic progenitors for skele-
tal muscle degenerative conditions [178]. Moreover, several 
studies showed that myogenic progenitors generated from 
induced pluripotent stem (iPS) cells are also able to partici-
pate in muscle regeneration and correct the dystrophic phe-
notype [179-182]. Further studies on the causal relationship 
of exosome-mediated processes are crucial in order to better 
delineate their involvement in striated muscle degenera-
tion/regeneration. Safety studies on the use of pluripotent 
stem cell derivatives are also desirable. It is reasonable to 
predict that more studies are expected on myogenic precur-
sors generated from pluripotent stem cells in combination 
with miRNA and novel gene editing technologies to treat 
muscle degeneration. Nevertheless, the results of those stud-
ies will require a deep comparison with those performed 
using adult stem cells, the ‘gold standard‘ for stem cell-based 
protocols in the last decades.  
ABBREVIATIONS USED 
CXCL = Chemochine Ligand 
DMD = Duchenne Muscular Dystrophy 
ECM = Extra Cellular Matrix 
FAPs = Fibro/Adipocyte Progenitors  
HGF = Hepatocyte Growth Factor 
HSC = Hematopoietic Stem Cells 
IFN-γ = Interferon-γ 
IGF = Insulin like Growth Factor  
IL = Interleukin 
LGMD2A = Limb Girdle Muscle Dystrophy-type 2 A 
MABs = mesoangiobalsts 
MAPKs = Mitogen Activated Protein Kinases 
MDSC = Muscle Derived Stem Cell 
MGF = Mechano Growth Factor 
miRNA = micro RNA 
MMP = Matrix Metalloproteinase 
MRFs = Myogenic Regulatory Factors 
MSC = mesenchymal stem cells 
MyHC = Myosin Heavy Chain 
NF-kB = Nuclear Factor kappa b 
NG2 = Neural-Glial-2 chondroitin sulphate proteo-
glycan  
NO = Nitric Oxide 
NOS = Nitric Oxide Synthase 
PICs = Pw1 expressing interstitial cells  
PI3K = Phosphatidylinositol 3 kinase 
SC = satellite cells 
Sk-34 = Skeletal muscle-derived CD34+/45- cells 
SP = Side Population 
S1P = Sphingosine-1-phosphate 
TCs = Telocytes 
TGFβ = Tumor Growth Factor beta 
TNFα = Tumor Necrosis Factor alpha 
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